At the news
? NEUTRALIMPACT 3/10 CLUSTER filed Apr 13, 2026 at 16:32 ET
Three United Therapeutics insiders, including the CEO and CFO, conducted open-market share sales totaling $158K over a 7-day period, concurrent with derivative exercises. The open-market selling is modest in magnitude relative to the company's $25.3B market cap.
- CEO Martine Rothblatt sold $271K worth of shares in two transactions ($20K on 2026-04-13 and $251K on 2026-04-10), but only $20K is from open-market selling; the rest stems from derivative exercises.
- EVP Paul Mahon sold $115K in open-market shares, following derivative exercises of 8,300 shares.
- CFO James Edgemond sold $23K in open-market shares, alongside derivative exercises of 20,000 shares.
- Total open-market selling by insiders: $158K over 7 days.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access